ePocrates Inc.

In a crowded field of companies marketing web-based handheld devices that allow physicians to perform a myriad of functions, ePocrates Inc. is trying to differentiate itself by offering less than its competition. That is, its idea is to ease physicians into using web-enabled devices with a package of prescription drug information.

In a crowded field of companies marketing web-based handheld devices that allow physicians to perform a myriad of functions—from prescribing to ordering lab tests to checking for drug interactions—ePocrates Inc. is trying to differentiate itself by offering less than its competition. Perhaps more to the point, the company's management is initially producing a narrow set of easy-to-use applications that it hopes will attract a broad practitioner customer base to which it eventually hopes to sell more sophisticated features. The idea is to ease physicians, who have proven surprisingly resistant to incorporating Internet technologies in their practices, into using web-enabled devices with a package of prescription drug information (e.g., dosing, counterindications, adverse reactions) that can readily be accessed at the point-of-care.

Major e-health companies like WebMDCorp.have learned the hard way that the single biggest barrier to creating the proverbial "seamless web"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.